2 Results for "

BCRP-mediated drug efflux

" in MedChemExpress (MCE) Product Catalog:
Products (2)

2 Results for "BCRP-mediated drug efflux" in MCE Product Catalog:

Cat. No.: HY-12758
CAS No.: 1346753-00-1
Purity:  99.16%
Target:  

BCRP

Research Areas:  

Cancer

YHO-13351 is an orally active ABCG2 inhibitor . YHO-13351 modulates the function of ABCG2, blocks BCRP-mediated compound efflux, downregulates the expression of breast cancer resistance protein at the post-transcriptional level, and reverses ABCG2-associated tolerance. YHO-13351 restores the toxicity of SN-38 to SN-38-resistant cancer cells and sensitizes cancer cells to Irinotecan. YHO-13351 is a water-soluble prodrug that is rapidly converted to YHO-13177 (HY-12757) in mice. YHO-13351 prolongs the median survival time of mice bearing cancer cell xenografts when combined with IMMU-132. YHO-13351 extends the survival time of tumor-bearing mice and inhibits the growth of xenograft tumors when combined with Irinotecan. YHO-13351 can be used for the research of breast cancer, gastric cancer, BCRP-mediated drug-resistant cancers, and cervical cancer .
loading...
    loading...
Cat. No.: HY-136940
CAS No.: 2377858-65-4
Target:  

BCRP

Research Areas:  

Cancer

Ac22(Az8)2​ is a selective BCRP inhibitor (EC50: 1-2 nM). Ac22(Az8)2 can restore the drug sensitivity of BCRP-overexpressing cells by inhibiting BCRP-ATPase activity, blocking drug efflux, and increasing intracellular drug accumulation. Ac22(Az8)2 can be used in the research of BCRP-mediated multidrug-resistant cancers .
loading...
    loading...